Results 1 to 10 of about 118,432 (256)

Hematopoietic stem cell transplantation

open access: yesStem Cells and Cloning: Advances and Applications, 2010
Eleftheria Hatzimichael1, Mark Tuthill21Department of Haematology, Medical School of Ioannina, University of Ioannina, Ioannina, Greece; 2Department of Medical Oncology, Hammersmith Hospital, Imperial College National Health Service Trust, London ...
Eleftheria Hatzimichael, Mark Tuthill
doaj   +5 more sources

One novel ACOT7–NPHP4 fusion gene identified in one patient with acute lymphoblastic leukemia: a case report

open access: yesBMC Medical Genomics, 2022
Background Acute lymphoblastic leukemia (ALL) is a type of heterogeneous hematopoietic malignancy that accounts for approximately 20% of adult ALL. Although ALL complete remission (CR) rate has increased to 85–90% after induction chemotherapy, 40–50% of ...
Xin Zong   +7 more
doaj   +1 more source

Real-world experience of treatment with thrombopoietin receptor agonists in anti-thymocyte globulin-naïve patients with aplastic anemia: an observational retrospective analysis in a single institution

open access: yesHematology, 2022
Objective To explore the efficacy and safety of thrombopoietin receptor agonists (TPO-RAs) without anti-thymocyte globulin (ATG) in ATG-naïve patients with aplastic anemia (AA) in a real-world setting.Methods We retrospectively evaluated treatment ...
Masaki Iino   +3 more
doaj   +1 more source

Identification of a novel HOOK3-FGFR1 fusion gene involved in activation of the NF-kappaB pathway

open access: yesCancer Cell International, 2022
Background Rearrangements involving the fibroblast growth factor receptor 1 (FGFR1) gene result in 8p11 myeloproliferative syndrome (EMS), which is a rare and aggressive hematological malignancy that is often initially diagnosed as myelodysplastic ...
Xuehong Zhang   +10 more
doaj   +1 more source

Hematopoietic Stem Cell Transplantation

open access: yesClinical laboratory science : journal of the American Society for Medical Technology, 2005
Hematopoietic stem cells have been shown to provide the best chance for long term patient engraftment in bone marrow transplantation, peripheral blood stem cell transplantation, and umbilical cord blood transplantation. Characteristics of these cells include the ability to divide without differentiating; presence in bone marrow, peripheral blood, and ...
M S, Wright-Kanuth, L A, Smith
  +5 more sources

CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia

open access: yesBiomolecules & Biomedicine, 2023
Quantification of measurable residual disease (MRD) correlates with the risk of leukemia recurrence in adults with B-cell acute lymphoblastic leukemia (ALL).
Lei-Ming Cao   +16 more
doaj   +1 more source

Homoharringtonine Exerts Anti-tumor Effects in Hepatocellular Carcinoma Through Activation of the Hippo Pathway

open access: yesFrontiers in Pharmacology, 2021
Hepatocellular carcinoma (HCC) is the most prevalent subtype of liver cancer with a mortality rate of approximately 3–6/100,000 and is the third leading cause of cancer-related death worldwide.
Haina Wang   +13 more
doaj   +1 more source

Mesenchymal stem cells in hematopoietic stem cell transplantation [PDF]

open access: yesCytotherapy, 2009
Mesenchymal stromal/stem cells (MSC) of bone marrow (BM) origin not only provide the supportive microenvironmental niche for hematopoietic stem cells (HSC) but are capable of differentiating into various cell types of mesenchymal origin, such as bone, fat and cartilage.
Minoo, Battiwalla, Peiman, Hematti
openaire   +2 more sources

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia

open access: yesJournal of Hematology & Oncology, 2017
Background The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with t ...
Ya-Zhen Qin   +14 more
doaj   +1 more source

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis

open access: yesExperimental Hematology & Oncology, 2017
Background Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have
Mauricio Sarmiento Maldonado   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy